Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651265 | 0.88 | CYP3A4 (0.31) | PDK2CYP3A4 | |
| SCHEMBL2649681 | 0.87 | GCK (0.34) | GCKTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2650347 | 0.87 | GCK (0.34) | GCKTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2651148 | 0.86 | GCK (0.35) | GCKTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2650108 | 0.81 | GCK (0.45) | GCK | |
| SCHEMBL2649950 | 0.78 | TAS1R3 (0.34) | TAS1R3TAS1R1CYP3A4TAS1R2 | |
| SCHEMBL2647437 | 0.78 | TAS1R3 (0.47) | TAS1R3TAS1R1CYP3A4TAS1R2 | |
| SCHEMBL2647434 | 0.78 | TAS1R3 (0.47) | TAS1R3TAS1R1CYP3A4TAS1R2 | |
| SCHEMBL2650928 | 0.77 | TAS1R3 (0.32) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2650469 | 0.75 | GCK (0.32) | GCKTAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311504-A1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002014312-A1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-21 | — | — | WO | disclosed |